Restoring
Life's Simple Joys Through Innovation
Life's Simple Joys Through Innovation
RAM Pharmaceuticals is a clinical-stage company driven by a clear mission: cancer treatment shouldn’t rob patients of life’s simplest joys—sharing a laugh, enjoying a meal, or whispering “I love you.” Through our Cancer Comfort Care Initiative, we are restoring dignity and bringing relief to those undergoing the fight of their lives.
Our flagship product, Triamdocaine, is a revolutionary therapy designed to alleviate the pain and discomfort caused by severe oral mucositis (SOM). Triamdocaine delivers precise, localized relief to help cancer patients reclaim their quality of life. With FDA IND approval secured, RAM Pharmaceuticals is leading the charge in supportive cancer care.
Beyond oncology, our commitment extends to dental health with Acyclonine MUM, a proven therapy providing targeted relief for oral conditions such as mucosal ulcerations, post-operative pain, and traumatic injuries. Through these innovations, RAM Pharmaceuticals is transforming care across two critical health sectors and inviting you to join us on this impactful journey.
Share Price: $1.00 | Minimum Investment Amount: $1,000.00*
*A 2% transaction fee applies to all investments.
Form C Offering Memorandum Investor Education
Transforming Lives, Elevating Care
Investing in RAM Pharmaceuticals means joining a mission to bring dignity and comfort to patients in need. With groundbreaking solutions, proven results, and a strong foundation, we are poised for lasting impact and market success.
Advancing Cancer Comfort Care
Our flagship therapy, Triamdocaine, is setting a new standard in supportive cancer care by addressing severe oral mucositis—a condition that affects millions of patients.
Pioneering Dental Relief
Acyclonine MUM has already demonstrated exceptional success in managing complex dental conditions, further showcasing RAM Pharmaceuticals’ commitment to improving lives.
Positioned in High-Growth Markets
With the rise in global cancer diagnoses and increasing demand for dental care, RAM Pharmaceuticals is strategically positioned to lead in two rapidly expanding healthcare sectors.
Strong Intellectual Property
Patents secured through 2039 provide a competitive edge and long-term market viability, solidifying RAM Pharmaceuticals’ leadership in therapeutic innovation.
A Meaningful Mission
RAM Pharmaceuticals is redefining what it means to care—delivering solutions that restore dignity, bring relief, and inspire hope.
The Challenge
Cancer treatment can disrupt life’s most basic joys, such as eating, speaking, and connecting with loved ones. Severe oral mucositis (SOM), a common side effect of radiation and chemotherapy, causes pain and discomfort that often prevents patients from living fully during treatment. Despite its prevalence, SOM remains underserved, with limited effective therapies available.
Our Solution
RAM Pharmaceuticals is changing this reality with Triamdocaine, a first-of-its-kind dry powder spray therapy designed to provide fast and effective relief for SOM. Combining anesthetic, antiviral, and anti-inflammatory agents, Triamdocaine delivers precise relief directly to the affected areas. RAM Pharmaceuticals is leading the way in bringing comfort back to cancer care.
Meeting Critical Needs with Proven Solutions
RAM Pharmaceuticals is addressing significant gaps in oncology and dental care with innovative therapies that improve patient lives.
Triamdocaine, our flagship product, directly addresses the needs of cancer patients experiencing severe oral mucositis (SOM), which affects up to 90% of those receiving combined radiation and chemotherapy.
In dental care, Acyclonine MUM has already demonstrated success in managing a wide range of oral conditions, from mucosal ulcerations to traumatic injuries. These proven results position RAM Pharmaceuticals as a trusted leader in both markets.
We have been cleared to proceed with Phase 2 clinical trials and have opted to conduct a proof-of-concept study before presenting our findings to the FDA. Our goal is to secure approval for a combined Phase 2/Phase 3 study. This strategy, proven effective by our clinical team in previous go-to-market efforts, has the potential to save approximately $1.5 million in Phase 2 clinical trial costs.
Additionally, our strong intellectual property portfolio, with patents secured through 2039, ensures a competitive edge in these rapidly growing sectors. Endorsements from dental professionals [Placeholder for testimonials] further validate the demand and efficacy of our therapies.
Compassion in Action: The Comfort Care Initiative
At RAM Pharmaceuticals, we believe care extends beyond medicine—it’s about restoring hope and dignity to those facing life’s toughest challenges. Through our Cancer Comfort Care Initiative, we are ensuring that patients undergoing treatment can reclaim life’s simple joys.
Triamdocaine is more than a therapy; it’s a lifeline for cancer patients struggling with severe oral mucositis. By alleviating pain and discomfort, it enables patients to focus on recovery while maintaining their ability to connect with loved ones.
Our commitment to comfort care also extends to dental health with Acyclonine MUM, a therapy that provides targeted relief for symptoms linked to Acute and Chronic Oral Mucosal Ulcerations, Post Op Pain Management, Oral Mucositis in Cancer Patients, Traumatic Dental Injuries, Aphthous Ulcers, Abscesses, Necrotizing Diseases, Lichen Planus, Pemphigus, and Stomatitis. Through these groundbreaking therapies, RAM Pharmaceuticals is transforming patient care and ensuring that comfort is a priority in every treatment plan.
Beyond innovation, we are raising awareness, collaborating with healthcare providers, and redefining what it means to provide patient-centered care. Together, we’re creating a future where comfort and dignity are integral to every treatment journey.
Leading the Way in Comfort Care
RAM Pharmaceuticals is uniquely positioned at the intersection of oncology and dental care, offering solutions that address unmet needs with innovation and compassion.
In oncology, severe oral mucositis (SOM) remains underserved, with limited therapies available. Triamdocaine stands out as a pioneering solution, offering targeted relief with a patented delivery system. Its unique formulation combines anesthetic, antiviral, and anti-inflammatory agents, providing patients with effective symptom management and a better quality of life.
In dental care, Acyclonine MUM offers a proven, targeted solution for oral pain and injuries, addressing conditions where current options often fall short.
With patents secured through 2039 and a dual focus on high-growth markets like Dental Support Organizations (companies that corporately manage many dental locations), RAM Pharmaceuticals is setting a new standard in supportive care. The DSO market size was valued at $137.77 billion in 2023 and is predicted to reach USD 583.68 billion by 2032. By delivering innovative therapies backed by clinical expertise and a commitment to patient outcomes, we are outpacing competitors and transforming healthcare for the better.
FAQs
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
The Common Stock (the "Shares") of [company name] (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions. The exceptions are sales to: (i) to the Company; (ii) to an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act; (iii) as part of an offering registered under the Securities Act with the SEC; or (iv) to a member of the Investor’s family or the equivalent, to a trust controlled by the Investor, to a trust created for the benefit of a member of the family of the Investor or equivalent, or in connection with the death or divorce of the Investor or other similar circumstance.
In the event of death, divorce, or similar circumstance, shares can be transferred to: ● The company that issued the securities ● An accredited investor ● A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: info@dealmakersecurities.com
At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
DealMaker Securities is serving as the intermediary for this offering. Once an offering ends, there is no guarantee that DealMaker Securities will have a relationship with the company. The company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
